493 - 504 of 7683 results

A First-Choice Treatment for the Inpatient Management of Stabilized Systolic HF Patients: An Evidence-Based Approach

Industry Webcast Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE Credit

Prevalence of heart failure (HF) is on the rise. Patients hospitalized with heart failure with reduced ejection fraction (HFrEF) are at considerable risk for readmission and mortality. This program will review the opportunity to reassess and influence the trajectory of these patients’ disease through inpatient initiation of a medication shown to help prevent rehospitalization due to HFrEF, reduce patient CV mortality, and improve patients’ quality of life. This program will review mechanistic evidence and provide rationale for its in-hospital initiation.


CardiologyNOW: A Pri-Med Virtual Conference

Earn up to 3.25 AMA PRA Category 1 Credits during this virtual conference headlined by expert cardiologist Peter Libby, MD. This half-day of education is designed to provide you with cardiology-focused sessions, provide opportunities for interactive Q&A, and offer timely medical updates to keep you informed on the most current clinical strategies relevant to your daily practice.


1 CME CREDIT

This presentation will review the various effects that COVID-19 may have on the cardiovascular system, with a focus on acute cardiac injury, myocarditis, and arrhythmias.


1 CME CREDIT

After implementing current guideline-directed medical management, there is still urgency to address residual cardiovascular risk. Among the drivers of residual cardiovascular risk, inflammation has generated considerable interest, first based on preclinical and biomarker studies in humans. More recently, translation has inspired clinical trials in this domain. This presentation will consider inflammation as a process that links traditional and nontraditional risk factors to atherothrombotic events.


Primary Care Pulse: Live on November 17, 2020

Pri-Med's new weekly CME/CE web series, Primary Care Pulse, features live conversations about timely topics and concerns facing primary care clinicians.


0.5 CME CREDIT

With ever-changing information on the 2019 novel coronavirus (COVID-19), it is hard to keep the facts straight! Join Drs. Charles Vega and Ty Gluckman as they team up live to discuss the most common reactions to the two approved COVID-19 mRNA vaccines, as well as evaluate the data on the efficacy of zinc and vitamin C on outpatients and single high dose of vitamin D among inpatients with SARS-CoV-2 infection.


FAQ for Seasonal Influenza: When, Who, and How to Manage?

Guest: Robert H. Hopkins, Jr, MD, MACP, FAAP & Charles Vega, MD, FAAFP


1 CME CREDIT

The amount of information available in the form of clinical trials and cohort studies is overwhelming, especially for primary care clinicians. Moreover, practice guidelines do not always reflect what is feasible or even best practice in specific clinical settings. This session will highlight some of the strongest research and guidelines that may alter clinical practice, with a focus on literature published in the past year. Every participant should take away several practical points that help them provide better patient care. The session will have an interactive component, which will allow for different perspectives and collective wisdom to make the best use of current evidence.


0.75 CME CREDIT

This lecture will discuss the appropriate follow-up of patients treated for the most common cancers. This will include breast cancer, colorectal cancer, Hodgkin's and non-Hodgkin's lymphoma, prostate cancer, and lung cancer. An in-depth discussion of the physical challenges and psychological impacts of a cancer diagnosis and its treatment will prepare you to help your patients with what lies ahead.


0.5 CME CREDIT

Unlike HIV with rates of mortality that decline yearly, TB remains the leading infectious cause of death worldwide, accounting for 1.3 million deaths in 2016. Approximately 2 billion people in the world and 10 to 15 million Americans have latent TB infection (LTBI). Although they are not infectious, up to 10% each year are at risk of progression to active disease, depending on their risk factors and co-morbidities. This presentation will compare modalities to diagnose LTBI: the tuberculin skin test (or PPD) and the interferon gamma release assay (e.g., the quantiferon gold blood test). The faculty will discuss which patients are at high risk for progression to TB disease and the role of preventive chemotherapy. Finally, you will learn more about the emerging global storm that awaits us as diabetes becomes epidemic and merges with TB, as there is a 2-4-fold increased risk for TB in patients with diabetes.